← Back to headlines
Jim Cramer Discusses Eli Lilly (LLY) and Novo Nordisk (NVO) in Weight Loss Market
Financial analyst Jim Cramer discussed Eli Lilly's (LLY) potential dominance in the weight loss market and how Novo Nordisk (NVO) might face increased competition from it.
9 Apr, 14:07 — 9 Apr, 14:07
Sources
Showing 1 of 1 sources
